Zigma 200mg Tablet CR contains Carbamazepine, an anticonvulsant and mood-stabilizing agent primarily used in the management of epilepsy, trigeminal neuralgia, and bipolar disorder. Each extended-release tablet delivers 200mg of Carbamazepine, ensuring a controlled and sustained release of the active ingredient to maintain therapeutic plasma concentrations over an extended period, thereby reducing dosing frequency and enhancing patient compliance. Carbamazepine acts by stabilizing hyperexcited nerve membranes, inhibiting repetitive neuronal firing, and reducing synaptic propagation of excitatory impulses, which contributes to its efficacy in seizure control and neuropathic pain relief. It is indicated for partial seizures with complex symptomatology, generalized tonic-clonic seizures, and mixed seizure patterns. Additionally, it is utilized in the treatment of trigeminal neuralgia to alleviate severe facial pain and as a mood stabilizer in bipolar affective disorder. Dosage should be individualized based on clinical response and tolerability, with careful titration to minimize adverse effects such as dizziness, drowsiness, nausea, and potential hematologic abnormalities. Regular monitoring of blood counts, liver function, and serum Carbamazepine levels is recommended to optimize therapy and detect toxicity early. Zigma 200mg Tablet CR should be used under medical supervision, considering potential drug interactions and contraindications.